SCHEMBL3396596

SCHEMBL3396596

COc1cc(C=CC(=O)c2ccccc2O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 1.00
PTGS2 P35354 2/20 1.00
MAOB P27338 6/20 0.85
ACHE P22303 1/20 0.85
ABCG2 Q9UNQ0 1/20 0.85
MAOA P21397 3/20 0.83
CXCL12 P48061 4/20 0.79
MAPT P10636 3/20 0.76
ALDH1A1 P00352 1/20 0.76
LMNA P02545 1/20 0.76
CHRNA7 P36544 1/20 0.76
KMT2A Q03164 2/20 0.74
NFKB1 P19838 2/20 0.74
NFKB2 Q00653 2/20 0.74
RELA Q04206 2/20 0.74
MEN1 O00255 1/20 0.74
TDP1 Q9NUW8 1/20 0.74
AR P10275 1/20 0.72
KDM4E B2RXH2 1/20 0.69
GAA P10253 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29427953 1.00 PTGS1 (1.00) PTGS1PTGS2MAOBACHEABCG2
SCHEMBL3396591 1.00 PTGS1 (1.00) PTGS1PTGS2MAOBACHEABCG2
SCHEMBL25195740 1.00 PTGS1 (1.00) PTGS1PTGS2MAOBACHEABCG2
SCHEMBL634190 0.92 MAOB (1.00) PTGS1PTGS2MAOBACHEABCG2
SCHEMBL25191295 0.92 PTGS1 (0.85) PTGS1PTGS2MAOBACHEABCG2
SCHEMBL634191 0.92 MAOB (1.00) PTGS1PTGS2MAOBACHEABCG2
SCHEMBL25223438 0.92 MAOB (1.00) PTGS1PTGS2MAOBACHEABCG2
SCHEMBL30385168 0.92 MAOB (1.00) PTGS1PTGS2MAOBACHEABCG2
SCHEMBL30384240 0.92 MAOB (1.00) PTGS1PTGS2MAOBACHEABCG2
SCHEMBL25195162 0.89 PTGS1 (0.81) PTGS1PTGS2MAOBACHEABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116783722-A Electrochemical cell, assembly thereof and method of making same 阿尔西姆能源公司 2023-09-19 CN claimed
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
CN-116783722-A Electrochemical cell, assembly thereof and method of making same 阿尔西姆能源公司 2023-09-19 CN disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-20220077449-A1 ELECTROCHEMICAL CELLS, COMPONENTS THEREOF, AND METHODS OF THEIR MANUFACTURE Alsym Energy, Inc. 2022-03-10 US disclosed
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-01-10 US disclosed
WO-2017132135-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-03 WO disclosed
US-9445606-B2 Use of 4-hydroxydihydrochalcones and their salts for enhancing an impression of sweetness SYMRISE AG (DE) 2016-09-20 US disclosed
US-20100233102-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS SYMRISE GMBH & CO. KG (DE) 2010-09-16 US disclosed
EP-1998636-B1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS SYMRISE GMBH & CO KG (DE) 2010-05-19 EP disclosed
EP-1998636-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS Symrise GmbH & Co. KG (DE) 2008-12-10 EP disclosed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed
WO-2007107596-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS SYMRISE GMBH & CO. KG (DE) 2007-09-27 WO disclosed
EP-1764363-A2 SUBSTITUTED ACETOPHENONEDERIVATIVES Riemser Arzneimittel AG (DE) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 PTGS1 2062/4885PTGS2 2748/4885MAOB 1213/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B PTGS1 522/4885PTGS2 704/4885MAOB 1004/4885
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF ESRRG, GPER1, ESR2 PTGS1 637/4885PTGS2 874/4885MAOB 3735/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 PTGS1 180/4885PTGS2 330/4885MAOB 2435/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 PTGS1 180/4885PTGS2 330/4885MAOB 2435/4885
US-20100233102-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS TAS2R4, TAS2R1, TAS2R20 PTGS1 2269/4885PTGS2 2908/4885MAOB 4319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.